Other Clinical Trial - Neoadjuvant FOLFIRINOX or Nab-paclitaxel With

Updated 04/26/2024

Status Active, not recruiting

Clinical Trial Summary

The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Borderline Resectable Pancreatic Cancer
Pancreatic Neoplasms

Clinical Trial Details

NCT number	NCT02717091
Study type	Interventional
Source	Nagoya University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 2015
Completion date	June 2023

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04617821` - AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer	Phase 3
	Suspended	`NCT04090463` - IORT on Borderline Resectable Pancreatic Cancer	Phase 2
	Terminated	`NCT04698915` - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer	Phase 2
	Not yet recruiting	`NCT06384560` - Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)	Phase 1/Phase 2
	Recruiting	`NCT03850769` - Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer	Phase 2
	Not yet recruiting	`NCT03443921` - Divestment for Artery-involved Pancreatic Cancer	N/A
	Recruiting	`NCT06345300` - NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study	Phase 2
	Terminated	`NCT02241551` - Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer	Phase 2
	Recruiting	`NCT04855331` - Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC	N/A